Company news
Zhejiang Medicine Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600216)"Zhejiang Medicine Co., Ltd."Announcement on Progress in Repurchasing Shares
November 3, 2026
(600216)"Zhejiang Medicine Co., Ltd."Report for Q3 2026
October 27, 2026
(600216)"Zhejiang Medicine Co., Ltd."Announcement on Progress in Repurchasing Shares
October 15, 2026
(600216)"Zhejiang Medicine Co., Ltd."Announcement on Progress in Repurchasing Shares
October 9, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 7, 2026
Announcement on Progress in Repurchasing Shares
September 1, 2026
Announcement on Resolutions of the 14th Meeting of the 10th Board of Directors
August 25, 2026
Announcement on Initial Repurchase of Shares through Call Auction
August 24, 2026
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase
July 17, 2026
Announcement on Resolutions of the 13th Meeting of the 10th Board of Directors
July 14, 2026
Announcement on Expiration of the Share Reduction Plan of a Shareholder Holding More Than 5% of the Company's Shares and No Share Reduction
July 7, 2026
Announcement on Implementation of Dividend Distribution for 2025
July 2, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 11, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 8, 2026
Announcement on Progress in Cooperation in Investment with a Private Fund
May 27, 2026
Announcement on Cooperative Investment with Private Fund
May 15, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
April 27, 2026
Announcement on the Self-Inspection Report on the Trading of Stocks by Insiders of Inside Information Related to the Spin-off of Affiliated Subsidiaries
April 24, 2026
Announcement on Resolutions of the 12th Meeting of the 10th Board of Directors
April 23, 2026
Announcement on 2025 Annual Profit Distribution Plan
April 10, 2026
Announcement on Plan of Shareholding Reduction through Call Auction by Shareholder with Over 5% Shares
March 16, 2026
Announcement on Initiation of Phase II Clinical Trial of ARX305
March 5, 2026
Announcement on C-Round Capital Increase of Subsidiary Novocodex Biopharmaceuticals with the Introduction of Strategic Investors and Waiver of Preemptive Subscription Rights
March 3, 2026
Announcement on No Shareholding Reduction upon Expiration of Shareholding Reduction Plan by Shareholder with Over 5% Shares
January 22, 2026
Announcement on the Results of Grants for the 2025 Restricted Stock Incentive Plan
January 6, 2026
Announcement on Progress in Change of Share Nature and Progress in Share Granting under 2025 Restricted Stock Incentive Plan
December 30, 2025
Announcement on Granting Restricted Stocks to Incentive Objects of 2025 Restricted Stock Incentive Plan
November 26, 2025
Self-Inspection Report on the Trading of Company's Stock by Information Insiders in 2025 Restricted Stock Incentive Plan
November 13, 2025
Publicity Description and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on the List of Incentive Objects in the 2025 Restricted Stock Incentive Plan
November 7, 2025
Abstract of 2025 Restricted Stock Incentive Plan (Draft)
October 27, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 10, 2025
2025 Semi-annual Report
August 25, 2025
Announcement on XC2309 Injection Obtaining Notice of Approval for Drug Clinical Trial
August 21, 2025
Announcement on Implementation Result of Shares Repurchase and Share Changes
August 12, 2025
Announcement on Progress in Repurchasing Shares
August 1, 2025
Announcement on Expected Increase in Semi-annual Performance for 2025
July 14, 2025
Announcement on Shares Repurchased Reaching 1% of the Company's Share Capital and Repurchase Progress
July 1, 2025
Announcement on Election Results of Employee Directors for the 10th Board of Directors
June 25, 2025
Announcement on Subsidiary Xinchang Pharmaceutical Factory Passing On-site Inspection by FDA of the United States
June 9, 2025
Announcement on Using Some Idle Self-owned Funds for Entrusted Wealth Management
May 30, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
May 12, 2025
Announcement on Convening the 2024 Annual Performance Briefing
May 8, 2025
Announcement on Resolution of the 5th Meeting of the 10th Board of Directors
April 23, 2025
Announcement on Obtaining Commitment Letter for Share Repurchase Loans from Financial Institutions
April 16, 2025
Announcement on Plan for Repurchasing Shares through Call Auction
April 14, 2025
Indicative Announcement on Proposal of Chairman to Repurchase Shares
April 9, 2025
Announcement on the Shareholding Reduction Plan for Shareholders Holding More than 5% of Shares through Call Auction
March 20, 2025
Announcement on Obtaining Drug Registration Certificate for Compound Sodium Acetate Ringer's Injection
February 27, 2025
Announcement on the Subsidiary Zhejiang Novus Pharmaceuticals Co., Ltd. Passing On-site Inspection by FDA
February 26, 2025
Announcement on Expected Increase in Annual Performance for 2024
January 22, 2025